Jazz Pharmaceuticals Plc: Q1 2026 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2026. Jazz Pharmaceuticals Plc is a global biopharmaceutical company focused on rare diseases, with a portfolio spanning sleep disorders (Xywav, Xyrem), epilepsy (Epidiolex), and oncology (Ziihera, Modeyso, Zepzelca, Rylaze). The company operates as a single business segment. Notable recent events include the completion of the Chimerix acquisition in April 2025 (adding Modeyso) and the sale of Sativex to CNX Therapeutics in October 2025.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,068.9 million | $897.8 million |
| Net Income | $293.1 million | $(92.5) million |
| Diluted EPS | $4.43 | $(1.52) |
| Operating Cash Flow | $408.2 million | $429.8 million |
| Cash & Investments | $2,874.3 million | $2,441.9 million |
| Total Debt (Principal) | $5,402.8 million | $5,402.8 million |
| Gross Margin | 87.5% | 88.3% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 19% year-over-year, driven by a 22% increase in net product sales. Key drivers included:
- Xywav: Sales rose 18% to $408.2 million due to increased volumes in narcolepsy and IH indications.
- Oncology: Sales surged 45% to $333.4 million, led by Zepzelca (+60%) and new contributions from Modeyso ($41.4 million) and Ziihera ($13.3 million).
- Epidiolex: Sales increased 15% to $249.8 million.
- Profitability: The company returned to profitability with $293.1 million in net income, compared to a $92.5 million loss in Q1 2025. This turnaround was significantly aided by a $122.8 million pre-tax gain from the sale of a Priority Review Voucher (PRV) in January 2026.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 31% to $352.7 million, primarily due to the absence of $172.0 million in Xyrem antitrust litigation settlement costs incurred in Q1 2025.
- Debt Reduction: While total debt principal remained stable, the company made voluntary repayments of $750.0 million on its Tranche B-2 Dollar Term Loan in January 2025, reducing interest expense by $13.8 million year-over-year.
Guidance, Outlook, and Risks
- Outlook: Management expects total revenues in 2026 to increase compared to 2025, driven by growth in oncology and epilepsy products. However, this is expected to be offset by a reduction in oxybate revenues due to decreased high-sodium authorized generic (AG) royalties and declining Xyrem sales following the launch of generic high-sodium oxybate products.
- Regulatory & Pipeline:
- Ziihera: An sBLA for first-line HER2-positive GEA is under FDA review with a PDUFA date of August 25, 2026.
- Modeyso: The Phase 3 ACTION confirmatory trial is ongoing for newly diagnosed diffuse midline glioma.
- JZP441: Development was discontinued in February 2026.
- Key Risks:
- Generic Competition: Ongoing patent litigation with Lupin, Teva, and others regarding Xywav. Generic high-sodium oxybate products (Amneal, Ascent) began dispensing in March 2026, impacting Xyrem/Xywav sales.
- Debt Obligations: The company carries significant debt ($5.4 billion principal), including $1.0 billion in 2026 Notes maturing in June 2026.
- Regulatory Scrutiny: Potential impacts from the Inflation Reduction Act (IRA) and Most-Favored-Nation (MFN) pricing proposals.
Investor Verification Checklist
- PRV Gain Sustainability: Verify the one-time nature of the $122.8 million gain from the PRV sale and its impact on normalized earnings.
- Xywav Patent Litigation: Monitor the status of consolidated lawsuits against Lupin and Teva, as a loss could accelerate generic entry.
- Debt Maturity Wall: Confirm refinancing plans or cash availability for the $1.0 billion 2026 Notes maturing in June 2026.
- Generic Oxybate Impact: Assess the rate of patient migration from Xywav/Xyrem to newly launched generic high-sodium oxybate products.
- Ziihera First-Line Approval: Track the FDA decision on the sBLA for first-line GEA treatment expected in August 2026.